John C. Araujo, MD, PhD
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2000 | Stritch School of Medicine Loyola University Chicago, Maywood, Illinois, US, Medicine, MD |
| 1996 | Georgetown University School of Medicine, Washington, DC, US, Microbiology and Immunology, PhD |
| 1991 | Fairfield University, Fairfield, Connecticut, US, Biology, BS |
Postgraduate Training
| 2003-2006 | Clinical Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2001-2003 | Clinical Residency, Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire |
| 2000-2001 | Clinical Internship, Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire |
Board Certifications
| 2008 | American Board of Internal Medicine-Medical Oncology |
| 2003 | American Board of Internal Medicine-Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2014
Instructor, Department of Emergency Department, Darmouth Hitchcock Medical Center, Lebanon, NH, 2002 - 2003
Institutional Committee Activities
Member, PCa SPORE Advisory Board, 2016 - Present
Committee Member, Faculty Senate, 2014 - Present
Committee Member, Clinical Effectiveness Subcommittee, 2013 - Present
Committee Member, Quality Officer, 2013 - Present
Committee Member, EHR Executive Core Committee, 2012 - Present
Chairman, Pharmacy and Therapeutics Committee, 2008 - Present
Committee Member, Council of Committee Chairs, 2008 - Present
Vice Chairman, Pharmacy and Therapeutics Committee, 2008 - 2008
Committee Member, Department Protocol Review, 2007 - Present
Honors & Awards
| Plumbism Secondary to Herbal Medicinal Ingestion, Dartmouth Hitchcock Medical Center | |
| Amyloidosis and MGUS Paraproteinemias, Dartmouth Hitchcock Medical Center |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN, de Bono JS, Petrylak DP, Fizazi K, Higano CS, Morris MJ, Rathkopf DE, Saad F, Ryan CJ, Small EJ, Kelly WK. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 41(15):JCO2202661, 2023. e-Pub 2023. PMID: 37040594.
- Spetsieris, N, Boukovala, M, Alafis, I, Davis, JW, Zurita-Saavedra, A, Wang, X, Tu, S, Chapin, BF, Aparicio, A, Corn, P, Wang, J, Subudhi, SK, Araujo, JC, Papadopoulos, JN, Pruitt, L, Weldon, J, Logothetis, CJ, Efstathiou, E. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. European Journal of Cancer 157:259-267, 2021. PMID: 34536949.
- Labanca E, Bizzotto J, Sanchis P, Anselmino N, Yang J, Shepherd PDA, Paez A, Antico-Arciuch V, Lage-Vickers S, Hoang AG, Tang X, Raso MG, Titus M, Efstathiou E, Cotignola J, Araujo J, Logothetis C, Vazquez E, Navone N, Gueron G. Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel. Oncogene 40(44):6284-6298, 2021. e-Pub 2021. PMID: 34584218.
- Alhalabi, O, Hasanov, E, Wilson, NR, Araujo, JC, Wang, J, Campbell, M, Goswami, S, Shah, AY, Gao, J, Msaouel, P, Tannir, NM. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease. International journal of cancer 149(2):387-393, 2021. PMID: 33739450.
- Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer 19(1):22-31.e5, 2021. e-Pub 2020. PMID: 32675015.
- Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
- Palanisamy N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, Labanca E, Manyam GC, Ravoori MK, Kundra V, Araujo JC, Efstathiou E, Pisters LL, Wan X, Wang X, Vazquez ES, Aparicio AM, Carskadon SL, Tomlins SA, Kunju LP, Chinnaiyan AM, Broom BM, Logothetis CJ, Troncoso P, Navone NM. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res 26(18):4933-4946, 2020. e-Pub 2020. PMID: 32576626.
- Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly WK. Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer. Ann Oncol 31(7):930-941, 2020. e-Pub 2020. PMID: 32289380.
- Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly WK. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectr 4(2):pkaa003, 2020. e-Pub 2020. PMID: 32368717.
- Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer 127:67-75, 2020. e-Pub 2020. PMID: 31986451.
- Efstathiou E, Titus M, Wen S, Troncoso P, Hoang A, Corn P, Prokhorova I, Araujo J, Dmuchowski C, Melhem-Bertrandt A, Patil S, Logothetis CJ. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. Eur Urol Oncol 3(1):119-127, 2020. e-Pub 2019. PMID: 31412017.
- Duplisea JJ, Petros FG, Li R, Fellman B, Guo CC, Czerniak BA, Siefker-Radtke AO, Araujo JC, Dinney CPN, Matin SF. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol 37(6):354.e19-354.e26, 2019. e-Pub 2019. PMID: 30777393.
- Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. J Clin Oncol 37(5):403-410, 2019. e-Pub 2018. PMID: 30576268.
- Etchebehere E, Brito AE, Kairemo K, Rohren E, Araujo J, Macapinlac H. Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?. Radiol Bras 52(1):33-40, 2019. PMID: 30804613.
- Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol 80(3):583-589, 2017. e-Pub 2017. PMID: 28730293.
- Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113(42):11919-11924, 2016. e-Pub 2016. PMID: 27698113.
- Maity SN, Titus MA, Gyftaki R, Wu G, Lu JF, Ramachandran S, Li-Ning-Tapia EM, Logothetis CJ, Araujo JC, Efstathiou E. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. Sci Rep 6:35354, 2016. e-Pub 2016. PMID: 27748439.
- Dayyani F, Zurita AJ, Nogueras-González GM, Slack R, Millikan RE, Araujo JC, Gallick GE, Logothetis CJ, Corn PG. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer 16:721, 2016. e-Pub 2016. PMID: 27599544.
- Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol 34(14):1652-9, 2016. e-Pub 2016. PMID: 26951312.
- Etchebehere EC, Araujo JC, Milton DR, Erwin WD, Wendt RE, Swanston NM, Fox P, Macapinlac HA, Rohren EM. Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy. Clin Nucl Med 41(4):268-73, 2016. e-Pub 2016. PMID: 26828141.
- Etchebehere EC, Milton DR, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution. Eur J Nucl Med Mol Imaging 43(1):8-20, 2016. e-Pub 2015. PMID: 26416392.
- Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. J Nucl Med 56(8):1177-84, 2015. e-Pub 2015. PMID: 26069307.
- Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121(1):69-76, 2015. e-Pub 2014. PMID: 25155428.
- Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG. Src signaling pathways in prostate cancer. Cancer Metastasis Rev 33(2-3):595-606, 2014. e-Pub 2014. PMID: 24522479.
- Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 74(6):1651-60, 2014. e-Pub 2014. PMID: 24473064.
- Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Matveev VB, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, Heidenreich A, de Bono JS, Begbie S, Hong JH, Richardet E, Gallardo E, Paliwal P, Durham S, Cheng S, Logothetis CJ. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol 14(13):1307-16, 2013. e-Pub 2013. PMID: 24211163.
- Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma. Am J Clin Oncol 36(5):450-4, 2013. e-Pub 2012. PMID: 22706175.
- Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clin Cancer Res 19(13):3621-30, 2013. e-Pub 2013. PMID: 23649003.
- Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ, Gallick GE. Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate 73(9):979-85, 2013. e-Pub 2013. PMID: 23371521.
- Ng L, Heck W, Lavsa S, Crowther D, Atkinson B, Xiao L, Araujo J. The Lack of Predictors for Rapid Progression in Prostate Cancer Patients Receiving Sipuleucel-T. Cancers (Basel) 5(2):511-18, 2013. e-Pub 2013. PMID: 24216988.
- Eser PO, Vanden Heuvel JP, Araujo J, Thompson JT. Marine-and plant-derived w-3 fatty acids differentially regulate prostate cancer cell proliferation. Mol Clin Oncol 76(1):444-452, 2013. e-Pub 2013. PMID: 24649190.
- Araujo JC, Trudel GC, Paliwal P. Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel. Cancer Manag Res 6(6):25-30, 2013. e-Pub 2013. PMID: 23516140.
- Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma. Eur Urol 62(6):1013-9, 2012. e-Pub 2012. PMID: 22771265.
- Ameri H, Araujo JC, Gombos DS. Leuprolide monotherapy for choroidal metastasis from prostate adenocarcinoma. Arch Ophthalmol 130(9):1225-6, 2012. PMID: 22965610.
- Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study. Cancer 118(1):63-71, 2012. e-Pub 2011. PMID: 21976132.
- Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 111(111):111ra121, 2011. PMID: 22133722.
- Araujo J, Logothetis C. Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev 36(6):492-500, 2010. e-Pub 2010. PMID: 20226597.
- Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, Ye X, deCrombrugghe B, Yu-Lee LY, Gallick GE, Lin SH. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 29(22):3196-207, 2010. e-Pub 2010. PMID: 20228840.
- Araujo JC, Poblenz A, Corn P, Parikh NU, Starbuck MW, Thompson JT, Lee F, Logothetis CJ, Darnay BG. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation. Cancer Biol Ther 8(22):2153-59, 2009. e-Pub 2009. PMID: 19855158.
- Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 2009. e-Pub 2009. PMID: 19636008.
- Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE. Targeting Src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68(9):3323-33, 2008. PMID: 18451159.
Other Articles
- Corn PG, Agarwal N, Araujo JC, Sonpavde G Taxane-based Combination Therapies for Metastatic Prostate Cancer. Eur Urol Focus 5(3):369-380, 2019. PMID: 29275145.
- Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 71(8):846-56, 2011. PMID: 21456067.
- Araujo J, Logothetis C Targeting Src signaling in metastatic bone disease. Int J Cancer 124(1):1-6, 2009. PMID: 18942061.
Abstracts
- Anselmino N, Labanca E, Shepherd PDA, Dong J, Yang J, Song X, Nandakumar S, Kundra R, Lee C, Schultz N, Zhang J, Araujo JC, Aparicio AM, Subudhi SK, Corn PG, Pisters LL, Ward JF, Davis JW, Vazquez ES, Gueron G, Logothetis CJ, Futreal A, Troncoso P, Chen Y, Navone NM. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series. Clin Cancer Res 30(10):2272-2285, 2024. PMID: 38488813.
- Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Stemberg C, Armstrong A, Carducci M, Chi K, De Bono J, Petrylak D, Fizazi K, Higano C, Morris M, Rathkopf D, Saad F, Ryan C, Small E, Kelly W. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Na¨ıve Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2023. PMID: None.
- Pilie P, Tidwell R, Viscuse P, Subudhi S, Corn P, Tu S, Araujo J, Zurits A, Wang J, Efstathiou E, Deinert J, Logothetis C, Thompson T, Aparicio A. Randomized phase II study of olaparib (Ola) maintenance following cabazitaxel-carboplatin induction chemotherapy (CabCarb) in men with aggressive variant prostate cancer (AVPC). 2023 GU ASCO, 2023. PMID: None.
- Viscuse P, Tidwell R, Liu J, Guo S, Vundavilli H, Zhang M, Subudhi S, Zurita A, Corn P, Tu S, Araujo J, Wang J, Efstathiou E, Wang J, Pilié P, Troncoso P, Zhang J, Wang W, Logothetis C, Aparicio A. DynAMo: A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC. J Clin Oncol 2022 ASCO, 2022. PMID: None.
- Alhalabi O, Wilson N, Xiao L, Navai N, Kamat A, Shah A, Araujo JC, Wang J, Goswami S, Gao J, Wang J, Guo C, Czerniak B, Corn P, Logothetis C, Dinney C, Campbell M, Tannir N, Siefker-Radtke A. Factors associated with improved outcomes in surgically resectable small cell urothelial cancer (SCUC). J Clin Oncology 40(6):495, 2022. PMID: None.
- Alhalabi O, Wilson N, Ajufo H, Lehner M, Hasanov E, Campbell M, Shah A, Wang J, Jonasch E, Araujo JC, Wang J, Gao J, Goswami S, Msaouel P, Tannir N. Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC). J Clin Oncology 40(6):356, 2022. PMID: None.
- Subudhi SK, Aparicio A, Troncoso P, Zhang J, Gumbs C, Wu CJ, Gao J, Vence LM, Blando JM, Corn PG, Araujo JC, Zurita AJ, Prokhorova IN, Van Alstine M, Logothetis C, Futreal A, Allison JP, Sharma P. Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa). J Clin Oncology, 2017 ASCO Annual Meeting 35, 2017. PMID: None.
- Corn P, Tu S, Zurita AJ, Subudhi SK, Araujo JC, Kim J, Jonasch E, Pagliaro LC, Siefker-Radtke AO, Wang J, Wang X, Heath EI, Logothetis C, Aparicio A. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncology, 2015 ASCO Annual Meeting 33, 2015. PMID: None.
- Chapin BF, Mcguire SE, Wang X, Troncoso P, Davis JW, Navai N, Subudhi SK, Zurita AJ, Araujo JC, Pettaway CA, Matin SF, Pisters LL, Ward JF, Tu S, Wang J, Le O, Logothetis CJ, Aparicio A. A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metastatic prostate cancer. None 33, 2015. PMID: None.
- De Bono JS, Pezaro CJ, Gillessen S, Shore ND, Nordquist LT, Efstathiou E, Araujo JC, Berry WR, Liu G, Vogelzang NJ, Omlin AG, Schotzinger RJ, Eisner JR, Moore WR. The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC. J Clin Oncology 33, 2015. PMID: None.
- Maity SN, Wu G, Lu JF, Hoang A, Landesman Y, McCauley D, Carlson R, Rashal T, Shacham S, Broom BM, Baggerly KA, Aparicio A, Efstathiou E, Araujo JC, Logothetis CJ. Effect of selinexor (KPT-330), a novel oral selective inhibitor of nuclear export (SINE), on tumor suppressors and cell cycle proteins in prostate cancer cells and regression of castration-resistant patient-derived xenograft tumor growth. J Clin Oncology 33, 2015. PMID: None.
- Etchebehere E, Araujo JC, Milton D, Fox PS, Swanston N, Macapinlac HA, Rohren E. Skeletal tumor burden on baseline 18F-fluoride PET/CT to predict bone marrow failure after radium-223. J Clin Oncol 33:11012, 2015. PMID: None.
- Bilen MA, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin SW, Logothetis C, Tu SM. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol, 2014. PMID: None.
- Corn PG, Tu SM, Zurita AJ, Araujo JC, Pagliaro LC, Logothetis CJ, Aparicio A. A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features. J Clin Oncol 32, 2014. PMID: None.
- Moore WR, Maity SN, Eisner JR, Garvey EP, Hoekstra WJ, Titus WA, Logothetis CJ, Araujo JC, Efstathiou E, Schotzinger RJ. The enzymology of the selective CYP17 lyase inhibitor, VT-464, and its effects in castration-resistant prostate cancer (CRPC) models. J Clin Oncol 32, 2014. PMID: None.
- Subudhi SK, Aparicio A, Zurita AJ, Araujo JC, Corn PG, Tu SM, Wang X, Harris DR, Winslow KA, Gao J, Logothetis CJ, Sharma P. Finite androgen deprivation therapy (ADT) plus ipilimumab (IPI) in men with hormon-naive metastatic prostate cancer (HN-MPCa). ESMO, 2014. PMID: None.
- Corn PG, Varkaris A, Tapia EM, Araujo CJ, Aparicio A, Tu SM, Zurita AJ, Efstathiou E, Qiao W, Wen S, Gallick GE, Logothetis C. Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. J Clin Oncol, 2013. PMID: None.
- Dayyani F, Varkaris A, Araujo JC, Song JH, Trudel GC, Logothetis C, Gallick GE. Serum insulin-like growth factor-1 levels in response to dasatinib-based regimens in bone-metastatic prostate cancer. J Clin Oncol 31, 2013. PMID: None.
- Araujo JC, Trudel GC, Saad F, Armstrong AJ, YU EY, Bellmunt J, Wilding G, McCaffrey J, Serrano SV, Malveev V, Efstathiou E, Oudard S, Morris MJ, Sizer B, Goebell PJ, DeBono JS, Paliwal P, Durham S, cheng S, Logothetis C. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. J Clin Oncol, 2013. PMID: None.
- Dayyani F, Gallick GE, Thompson JT, Trudel GC, Logothetis C, Araujo JC. Correlation of dasatinib (DAS) peak levels with interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) levels in patients with castration-resistant progressive prostate cancer (CRPC). J Clin Oncol 28(15S):382s, 2010. PMID: None.
- Araujo J, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib and docetaxel combination treatment for patients with castration-resistance progressive prostate cancer: A phase I/II study (CA180086). J Clin Oncol 27(15S):249s, 2009. PMID: None.
- Araujo J, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick G, Trudel GC, Paliwal P, Logothetis CJ. Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer: analysis of Study CA180-086. Eur J Cancer Suppl 7:415S, 2009. PMID: None.
- Plimack ER, Jonasch E, Bekele BN, Smith LA, Araujo JC, Tannir NM. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): A phase II study. J Clin Oncol 26(15S):277s, 2008. PMID: None.
- Jonasch E, Woods, CG, Matin S, Tamboli P, Do K, Pagliaro C, Aparicio A, Araujo J, Tannir NM. Presurgical bevacizumab in patients with metastatic lear cell renal cell carcinoma: A phase II study. J Clin Oncol 26(15S):275s, 2008. PMID: None.
- Zurita AJ, Ward JF, Araujo JC, Ca P, Pisters LL, Dieringer P, Troncoso P, Logothetis CJ. Presurgical sunitinib malate and androgen ablation in patients with localized prostate cancer at high risk for recurrence. J Clin Oncol 26(15S):271s, 2008. PMID: None.
- Aparicio AM, Lin AM, Araujo JC, Logothetis JC, Kim J, Pagliaro LC, Tu S, Guo C, Jones D, Thall P, Mathew P. Use of clinical features to select a chemotherapy-responsive variant of aggressive prostate cancer. J Clin Oncol 26(15S):271s, 2008. PMID: None.
- Araujo JC, Jonasch E, Tannir N, Bekele BN, Lin E, Plimack ER. Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon. J Clin Oncol 26(15S):276s, 2008. PMID: None.
Grant & Contract Support
| Title: | A Phase 2 Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma Following Systemic Therapy |
| Funding Source: | Boehringer Ingelheim Pharm/Univ of Alabama |
| Role: | Principal Investigator-MDACC |
| Title: | MD Anderson Cancer Center Prostate Cancer SPORE - Project 2: Targeting Tumor Microenvironment-induced Therapy Resistance in Prostate Cancer Bone Metastasis |
| Funding Source: | NIH/NCI |
| Role: | Clinical Co-Leader |
| Title: | Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| Title: | An Observation, Open Label Study of Alpharadin (Radium 223) in Patients with Castrate Resistant Prostate Cancer Bone Metastases (NCT02135484) |
| Funding Source: | Bayer Healthcare |
| Role: | PI |
| Title: | Biomarker Companion Study to Clinical Protocol 2008-0576 |
| Funding Source: | Bristol-Myers Squibb |
| Role: | PI |
| Title: | A Phase 2 Study of Oral Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma |
| Funding Source: | Karyopharm Therapeutics |
| Role: | PI |
| Title: | A Phase 1/11 Open-Label. Multiple-Dose Study to Evaluate the Safety, Tolerability, Phatmacokinetice, and Pharmacodynamics of VT-464 in Chemotherapy_Naive Patients with Castration-Refractory Prostate Cancer |
| Funding Source: | Viamet Pharmaceuticals |
| Role: | PI |
| Title: | Evaluation of TAK1 as a Tumor Suppressor Gene in Prostate Cancer |
| Funding Source: | Elsa U. Pardee Foundation |
| Role: | unknown |
| Title: | The University of Texas MD Anderson Cancer Center Prostate SPORE |
| Funding Source: | NIH/NCI |
| Role: | Co-Program Leader |
| Title: | MD Anderson Cancer Center Prostate Cancer SPORE - Project 2: Targeting Tumor Micro-environments Induced Therapy Resistance in Prostate Cancer Bone Metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-Leader, Project 3 |
| Title: | A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer |
| Funding Source: | Bristol Myers Squibb |
| Role: | PI |
| Title: | Role of Fibroblast Growth Factor 9 in Prostate Cancer Bone Metastasis |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Principal Investigator-MDACC |
| Title: | NO TITLE PROVIDED |
| Funding Source: | U T M. D. Anderson Cancer Center |
| Role: | Postdoctoral Fellow |
| Title: | Research Training in Academic Medical Oncology |
| Funding Source: | NIH/NCI |
| Role: | Postdoctoral Fellow |
Patient Reviews
CV information above last modified November 19, 2024